Plain-English translation of NCT06789848 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications called and to treat advanced liver cancer and bile duct cancer. These are cancers that have either spread or cannot be surgically removed. The study is specifically for people whose cancer did not respond to or came back after previous immunotherapy treatments.
Many patients with advanced liver and bile duct cancers do not respond well to existing immunotherapy treatments, or their cancer comes back after treatment. This trial is testing whether this new two-drug combination might work better for these hard-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
You would come to the clinic on the first day of each 21-day cycle to receive infusions of the two medications through an IV (intravenous line). Each clinic visit would last about 4–5 hours. You would continue receiving the medication as long as your cancer is not getting worse, as determined by imaging scans and blood tests done during the study. You would be monitored closely for side effects and how well the treatment is working.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Texas Southwestern Medical Center
Collaborators
Akesobio, Josephine Hughes Sterling Foundation
Enrollment target
~64 participants
Started
February 2025
Primary completion
May 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Carrie Manwaring
University of Texas Southwestern Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.